EDAP TMS (FOCL)
NASDAQ:FOCL
Want to see FOCL full AI Analyst Report?
Top Page
EDAP TMS
(NASDAQ:FOCL)
Select Model
Select Model
Rating:55Neutral
Price Target:
$4.50
▲(28.94% Upside)
Action:Reiterated
Date:06/02/26
The score is held back primarily by weak financial performance—ongoing losses and negative free cash flow—despite solid top-line growth and low leverage. Technicals are supportive with price above major moving averages and positive momentum indicators, while earnings commentary and corporate actions point to strong HIFU momentum and a clearer strategic focus, tempered by higher expenses, cash drawdown, and potential dilution from financing.
Positive Factors
Rapid HIFU Adoption
Sustained double‑digit system sales and sharply higher procedure volumes indicate durable clinical adoption and growing installed base. That expansion supports recurring consumable, service and upgrade revenue streams that scale with placements and underpin long‑term revenue growth.
Negative Factors
Persistent Cash Burn
Sustained negative operating and free cash flow creates ongoing financing needs and heightens funding risk absent rapid margin improvement or cash generation. Even with projectable revenue growth, continued cash burn can force dilutive financing or constrain investment in commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid HIFU Adoption
Sustained double‑digit system sales and sharply higher procedure volumes indicate durable clinical adoption and growing installed base. That expansion supports recurring consumable, service and upgrade revenue streams that scale with placements and underpin long‑term revenue growth.
Read all positive factors
EDAP TMS (FOCL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$173.17M
Dividend YieldN/A
Average Volume (3M)36.57K
Price to Earnings (P/E)―
Beta (1Y)0.98
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees310
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.49
Shares Outstanding37,481,987
10 Day Avg. Volume28,395
30 Day Avg. Volume36,573
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)6.44
Price to Sales (P/S)1.77
P/FCF Ratio-5.84
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue3.76
Enterprise Value/Gross Profit8.54
Enterprise Value/Ebitda-11.93
Forecast
1Y Price Target
$10.00Price Target Upside186.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.88
Revenue Forecast (FY)$67.19M
EDAP TMS Business Overview & Revenue Model
Company Description
EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) ...
How the Company Makes Money
EDAP makes money by selling capital equipment (medical devices) and generating recurring revenue tied to the installed base. A primary revenue stream is the sale of its HIFU systems (e.g., urology therapeutic ultrasound platforms) to healthcare pr...
EDAP TMS Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
55
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 39.74M | 70.75M | 69.35M | 65.32M | 57.92M | 52.08M |
| Gross Profit | 17.48M | 30.09M | 28.73M | 26.39M | 25.43M | 21.77M |
| EBITDA | -12.51M | -21.78M | -20.15M | -20.02M | -3.63M | -1.24M |
| Net Income | -18.57M | -29.34M | -20.57M | -22.90M | -3.08M | 827.39K |
Balance Sheet | ||||||
| Total Assets | 72.06M | 79.00M | 89.12M | 101.13M | 107.92M | 87.82M |
| Cash, Cash Equivalents and Short-Term Investments | 15.01M | 20.45M | 30.90M | 48.02M | 67.38M | 53.66M |
| Total Debt | 27.79M | 27.68M | 14.41M | 9.37M | 10.02M | 11.38M |
| Total Liabilities | 61.96M | 59.58M | 46.77M | 38.25M | 31.47M | 30.90M |
| Stockholders Equity | 10.10M | 19.41M | 42.35M | 62.88M | 76.45M | 56.92M |
Cash Flow | ||||||
| Free Cash Flow | -7.82M | -21.40M | -16.12M | -17.14M | -3.82M | 4.79M |
| Operating Cash Flow | -5.37M | -16.46M | -14.69M | -15.87M | -3.18M | 5.26M |
| Investing Cash Flow | -2.45M | -5.73M | -4.46M | -4.70M | -2.50M | -1.94M |
| Financing Cash Flow | 10.12M | 8.64M | 5.01M | -984.90K | 22.85M | 23.95M |
EDAP TMS Technical Analysis
Positive
3.49
Price Trends
3.79
Positive
4.00
Positive
3.21
Positive
Market Momentum
0.23
Negative
64.78
Neutral
76.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FOCL, the sentiment is Positive. The current price of 3.49 is below the 20-day moving average (MA) of 4.31, below the 50-day MA of 3.79, and above the 200-day MA of 3.21, indicating a bullish trend. The MACD of 0.23 indicates Negative momentum. The RSI at 64.78 is Neutral, neither overbought nor oversold. The STOCH value of 76.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FOCL.
EDAP TMS Risk Analysis
EDAP TMS disclosed 42 risk factors in its most recent earnings report. EDAP TMS reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
EDAP TMS Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $179.64M | -20.55 | -90.62% | ― | 18.22% | 59.78% | |
58 Neutral | $119.88M | 17.60 | 3.81% | ― | 2.25% | -19.05% | |
56 Neutral | $64.53M | 34.91 | 3.68% | ― | -0.32% | ― | |
55 Neutral | $173.17M | -5.55 | -148.90% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $14.65M | -0.68 | -211.73% | ― | 8.92% | 17.49% | |
44 Neutral | $43.33M | -1.73 | -81.52% | ― | 54.38% | 7.25% |
* Healthcare Sector Average
FOCL
EDAP TMS
4.56
2.78
156.18%
APYX
Apyx Medical
4.47
2.80
167.66%
FONR
Fonar
19.09
4.61
31.79%
NSPR
InspireMD
0.88
-1.62
-64.80%
XTNT
Xtant Medical Holdings
0.46
-0.24
-34.53%
ICCM
Icecure Medical
4.37
-25.51
-85.39%
EDAP TMS Corporate Events
Business Operations and StrategyFinancial Disclosures
EDAP TMS pivots to pure-play robotic focal therapy
Positive
Jun 1, 2026
On June 1, 2026, FocalTherics presented an extensive Investor Day update at the FocalTherics Investor Day, outlining its transformation into a high-growth, pure-play robotic focal therapy company. Management highlighted its plan to discontinue non...
Business Operations and StrategyDelistings and Listing Changes
EDAP TMS Rebrands to FocalTherics, Refocuses on HIFU
Positive
May 29, 2026
On May 29, 2026, EDAP TMS announced it would begin operating under the corporate name FocalTherics and switch its Nasdaq ticker from EDAP to FOCL effective at the market open on June 1, 2026, while its legal name remains EDAP TMS S.A. for now. The...
Private Placements and Financing
EDAP TMS Draws EIB Tranche, Issues New Warrants
Positive
Apr 2, 2026
EDAP TMS S.A. has drawn a €12.0 million second tranche under its previously announced €36.0 million credit facility with the European Investment Bank, after satisfying the required conditions, with the funds requested on April 1, 2026 ...
Business Operations and StrategyProduct-Related Announcements
EDAP TMS Showcases Focal One HIFU at Oppenheimer Conference
Positive
Mar 18, 2026
On March 18, 2026, EDAP TMS will present at the Oppenheimer 36th Annual Healthcare MedTech Services Conference, highlighting its Focal One robotic HIFU technology as a best-in-class, image-guided focal therapy for prostate cancer within a roughly...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.